Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin

详细信息    查看全文

• 作者：Keishiro Fukumoto ; Eiji Kikuchi ; Shuji Mikami ; Akira Miyajima ; Mototsugu Oya
• 关键词：Urinary bladder neoplasms ; Carcinoma ; Transitional cell ; Lymphatic metastasis ; Recurrence ; Disease progression
• 刊名：BMC Urology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：890 KB
• 参考文献：1.Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–53.PubMed CrossRef
  2.Hemdan T, Johansson R, Jahnson S, Hellstrom P, Tasdemir I, Malmstrom PU, et al. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guerin with epirubicin and interferon-alpha2b in patients with T1 bladder cancer. J Urol. 2014;191(5):1244–9.PubMed CrossRef
  3.Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol. 2012;62(1):118–25.PubMed CrossRef
  4.Lebret T, Neuzillet Y. Indication and timing of cystectomy in high-risk bladder cancer. Curr Opin Urol. 2012;22(5):427–31.PubMed CrossRef
  5.Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol. 2009;27(3):347–51.PubMed CrossRef
  6.Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. 2008;53(1):146–52.PubMed CrossRef
  7.Roghmann F, Trinh QD, Braun K, von Bodman C, Brock M, Noldus J, et al. Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy. Int J Urol. 2014;21(2):143–9.PubMed CrossRef
  8.Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992–1001.PubMed CrossRef
  9.Joudi FN, Smith BJ, O’Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175(5):1634–40.PubMed CrossRef
  10.Denzinger S, Otto W, Fritsche HM, Roessler W, Wieland WF, Hartmann A, et al. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol. 2007;14(11):995–9.PubMed CrossRef
  11.Kakiashvili DM, van Rhijn BW, Trottier G, Jewett MA, Fleshner NE, Finelli A, et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment. BJU Int. 2011;107(4):540–6.PubMed CrossRef
  12.Lodde M, Mian C, Mayr R, Comploj E, Trenti E, Melotti R, et al. Recurrence and progression in patients with non-muscle invasive bladder cancer: Prognostic models including multicolor fluorescence in situ hybridization molecular grading. Int J Urol. 2014;21(10):968–72.PubMed CrossRef
  13.Mollberg NM, Bennette C, Howell E, Backhus L, Devine B, Ferguson MK. Lymphovascular invasion as a prognostic indicator in stage I non-small cell lung cancer: a systematic review and meta-analysis. Ann Thorac Surg. 2014;97(3):965–71.PubMed CrossRef
  14.Rakha EA, Martin S, Lee AH, Morgan D, Pharoah PD, Hodi Z, et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 2012;118(15):3670–80.PubMed CrossRef
  15.Lim SB, Yu CS, Jang SJ, Kim TW, Kim JH, Kim JC. Prognostic significance of lymphovascular invasion in sporadic colorectal cancer. Dis Colon Rectum. 2010;53(4):377–84.PubMed CrossRef
  16.Kim SH, Yang HK, Moon KC, Lee ES. Localized non-conventional renal cell carcinoma: prediction of clinical outcome according to histology. Int J Urol. 2014;21(4):359–64.PubMed CrossRef
  17.Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. J Urol. 2005;174(6):2181–5.PubMed CrossRef
  18.Fujita K, Tanigawa G, Imamura R, Nakagawa M, Hayashi T, Kishimoto N, et al. Preoperative serum sodium is associated with cancer-specific survival in patients with upper urinary tract urothelial carcinoma treated by nephroureterectomy. Int J Urol. 2013;20(6):594–601.PubMed CrossRef
  19.Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, et al. Post-operative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinoma without metastasis. BJU Int. 2014;114(5):733–40.PubMed CrossRef
  20.Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. EAU guidelines on testicular cancer: 2011 update. Eur Urol. 2011;60(2):304–19.PubMed CrossRef
  21.Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 Pt 1):2414–22.PubMed CrossRef
  22.Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010;105(10):1402–12.PubMed CrossRef
  23.Lopez JI, Angulo JC. The prognostic significance of vascular invasion in stage T1 bladder cancer. Histopathology. 1995;27(1):27–33.PubMed CrossRef
  24.Andius P, Johansson SL, Holmang S. Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology. 2007;70(4):758–62.PubMed CrossRef
  25.Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, et al. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 2009;182(6):2625–30.PubMed CrossRef
  26.Branchereau J, Larue S, Vayleux B, Karam G, Bouchot O, Rigaud J. Prognostic value of the lymphovascular invasion in high-grade stage pT1 bladder cancer. Clin Genitourin Cancer. 2013;11(2):182–8.PubMed CrossRef
  27.Sato M, Yanai H, Morito T, Oda W, Shin-no Y, Yamadori I, et al. Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder. Pathol Int. 2011;61(8):456–60.PubMed CrossRef
  28.Lebret T, Becette V, Herve JM, Molinie V, Barre P, Lugagne PM, et al. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol. 2000;37(6):654–9.PubMed CrossRef
  29.Lebret T, Watson RW, Molinie V, Poulain JE, O’Neill A, Fitzpatrick JM, et al. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur Urol. 2007;51(1):161–6.PubMed CrossRef
  30.Berman DM, Kawashima A, Peng Y, Mackillop WJ, Siemens DR, Booth CM. Reporting trends and prognostic significance of lymphovascular invasion in muscle-invasive urothelial carcinoma: a population-based study. Int J Urol. 2014;22(2):163–70.PubMed CrossRef
  
• 作者单位：Keishiro Fukumoto (1)
  Eiji Kikuchi (1)
  Shuji Mikami (2)
  Akira Miyajima (1)
  Mototsugu Oya (1)
  
  1. Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-0016, Japan
  2. Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan
  
• 刊物主题：Urology/Andrology; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2490

文摘

Background Lymphovascular invasion (LVI) is an important step in the process of tumor dissemination and metastasis outside the primary organ, but the relationship between LVI and the prognosis of T1 non-muscle invasive bladder cancer (NMIBC) has not been fully evaluated. Accordingly, the present study was performed to evaluate whether LVI had an impact on the clinical outcome in patients with T1 NMIBC.